SCHEMBL196487

SCHEMBL196487

CC(=O)NCc1ccc(Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.70
MEN1 O00255 4/20 0.70
CYP2C19 P33261 2/20 0.66
CYP2C9 P11712 1/20 0.66
ALDH1A1 P00352 5/20 0.62
RAB9A P51151 4/20 0.62
MAPT P10636 3/20 0.62
POLB P06746 1/20 0.62
HDAC1 Q13547 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HPGD P15428 3/20 0.59
NPC1 O15118 2/20 0.59
WDR91 A4D1P6 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.56
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.53
THRB P10828 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12133623 0.89 KMT2A (0.76) KMT2AMEN1ALDH1A1RAB9AMAPT
SCHEMBL23747418 0.87 RAB9A (0.78) KMT2AMEN1RAB9APOLBNPC1
Cadaverine Tartrate SCHEMBL9937385 0.85 KMT2A (0.53) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL11296874 0.83 CNR1 (0.61) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL5987795 0.83 MAPT (0.68) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL24576009 0.83 MEN1 (1.00) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL9431727 0.82 KMT2A (0.63) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL202718 0.81 MEN1 (0.61) KMT2AMEN1CYP2C19CYP2C9ALDH1A1
SCHEMBL3612554 0.81 KMT2A (0.66) KMT2AALDH1A1RAB9AMAPTPOLB
SCHEMBL1951513 0.81 KMT2A (0.66) KMT2AALDH1A1RAB9AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280707-B1 BICYCLIC QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-12-20 EP claimed
CN-111187176-B Method for preparing N-vinyl amide compound under catalysis of copper salt 浙江工业大学 2022-11-25 CN claimed
CN-111187176-A Method for preparing N-vinyl amide compound under catalysis of copper salt 浙江工业大学 2020-05-22 CN claimed
US-8148537-B2 Substituted acetophenones useful as PDE4 inhibitors LEO PHARMA A/S (DK) 2012-04-03 US claimed
EP-2125736-B1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA AS (DK) 2011-03-30 EP claimed
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA (DK) 2010-02-11 US claimed
CN-101611005-A Be used as the acetophenones of the replacement of PDE4 inhibitor LEO PHARMA AS (DK) 2009-12-23 CN claimed
EP-2125736-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS Leo Pharma A/S (DK) 2009-12-02 EP claimed
WO-2008077404-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA A/S (DK) 2008-07-03 WO claimed
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2006-03-16 US claimed
EP-1472216-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE Axys Pharmaceuticals (US) 2004-11-03 EP claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 WO claimed
EP-0705251-A1 IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS Knoll AG (DE) 1996-04-10 EP claimed
WO-1995000493-A1 IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS KNOLL AG (DE) 1995-01-05 WO claimed
EP-0343894-B1 BENZAMIDE PROTEASE INHIBITORS PFIZER INC. (US) 1992-06-10 EP claimed
US-4948901-A ANTI-PLASMIN AND ANTI-THROMBIN AGENTS PFIZER INC. (US) 1990-08-14 US claimed
EP-0343894-A1 Benzamide protease inhibitors PFIZER INC. (US) 1989-11-29 EP claimed
CN-122036718-A ALK5 inhibitor and preparation method and application thereof 安炎达医药技术(广州)有限公司 2026-05-15 CN disclosed
US-4874864-A ANTIPLASMIN, ANTITHROMBIN AGENTS PFIZER INC. (US) 1989-10-17 US disclosed
US-4590297-A Novel 9-substituted carbacyclin analogs THE UPJOHN COMPANY (US) 1986-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035908-A1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS PDE4A, PDE4B, PDE3B KMT2A 3607/4885MEN1 4170/4885CYP2C19 437/4885
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 KMT2A 100/4885MEN1 4206/4885CYP2C19 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.